Actively Recruiting
Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease
Led by Beijing Children's Hospital · Updated on 2025-06-19
48
Participants Needed
1
Research Sites
259 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigate whether the addition of recombinant humanized anti-CD25 monoclonal antibody to the conventional EBV-T/NK LPD conditioning regimen can prevent acute and chronic GVHD after transplantation, improve the severity of GVHD and have a corresponding impact on other related post-transplant complications such as poor engraftment, thrombotic microvascular disease, early EBV reactivation and relapse.
CONDITIONS
Official Title
Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with EBV-T/NK lymphoproliferative disease according to ICC2022 criteria
- Planning to undergo allogeneic hematopoietic stem cell transplantation at the study hospital
- Aged 18 years or younger
- Signed informed consent form
- Donor meets at least one of these: 40 years or older; unrelated donor or haploidentical female or collateral donor with at least one locus mismatch; pre-transplant CD3 count ≥4 x 10^8/kg; primary disease in HLH flare or active phase; ATG (or equivalent) dose less than 10 mg/kg
You will not qualify if you...
- Expected survival of 3 months or less due to multiple organ failure
- Did not sign the informed consent form
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Children's Hospital Capital Medical University
Beijing, China, 100045
Actively Recruiting
Research Team
J
Jun Yang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here